Product Details

The thrombosis risk panel is a DNA test analysing variations in prothrombotic genes, Factor II and Factor V. The report provides insight into increased risk for thrombosis and personalised recommendations to better manage this risk.

Thrombophilia is a blood coagulation disorder that increases the risk of developing venous thromboembolism (VTE) resulting in deep vein thrombosis (DVT) or pulmonary embolism (PE). Genetic screening of thrombophilia in at-risk individuals can be useful in tailoring the management of  the disorder and improve patient outcomes.

Thrombophilic risk is multifactorial with both genetic and acquired risk factors. Acquired risk factors for VTE include oral contraceptive use, neoplasia, travel-related or prolonged immobility, and recent surgery. The most common genetic risk factor for inherited thrombophilia is the G1691A mutation found in the Factor V gene, followed by the G20210A mutation found in the Factor II gene.

Consider this test in patients who present with previous or family history of thrombosis, as a pre-emptive screening for those undergoing surgery or for frequent travellers. The test should also be considered in women who are considering falling pregnant and those who have previously suffered pregnancy loss (alongside GrowBaby), as well as those women considering hormonal contraceptive use or hormone replacement therapy (HRT).

Factor V functions as a cofactor to allow Factor Xa to activate the enzyme thrombin, and in turn cleaves fibrinogen to form fibrin. This polymerizes to form the dense meshwork that makes up the majority of a clot. Activated protein C (aPC) is a natural anticoagulant that acts to limit the extent of clotting by cleaving and degrading factor V.

The Factor II gene encodes the coagulation factor II, or prothrombin, which is a vitamin K–dependent proenzyme that functions in the area of blood coagulation. Factor II is a precursor to thrombin, which converts fibrinogen into fibrin, which in turn strengthens a protective clot.

The DNA and the original sample material are destroyed after 3 months, so that there are no names or other identifiers on the samples. The samples are analysed only for the SNPs that are included in the tests at DNALife, and no other research or analyses are performed without a separate permission from the patient. We do not give or sell the results to any third parties.